TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019 07; 33(7):1747-1758.